Results 181 to 190 of about 120,029 (315)

Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell   +6 more
wiley   +1 more source

Risk factors for deferral due to low hematocrit and iron depletion among prospective blood donors in a Brazilian center

open access: diamond, 2015
Eloísa Tedeschi Dauar   +5 more
openalex   +1 more source

Cross‐lagged assessment between indices of leisure time physical activity and domains of quality of life after electrical stimulation training in persons with spinal cord injury: An exploratory trial

open access: yesPM&R, EarlyView.
Abstract Background An existing association was noted between leisure time physical activity (LTPA) and quality of life (QOL) after spinal cord injury (SCI). Furthermore, electrical stimulation exercise program has been shown to improve domains of QOL.
Ashraf S. Gorgey   +4 more
wiley   +1 more source

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen   +6 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Home - About - Disclaimer - Privacy